drugset / Trial / NCT02605863
Enzalutamide for Bladder Cancer Chemoprevention
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).
Timeline
- Start
- 2016-01
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |